Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Rituximab with AHSCT for Multiple Sclerosis
NCT05078177Phase 1Unknown
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rituximab in multiple sclerosis (MS), sponsored by First Saint Petersburg State Medical University. Primary endpoint: Multiple sclerosis progression free survival at 365 days. Status: unknown.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05078177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078177.